



November 3, 2016

Acceleron Announces New Data Presentations at the 58th American Society of Hematology Annual Meeting and Exposition

- Oral and poster presentations span multiple hematologic diseases including myelodysplastic syndromes, beta-thalassemia and myelofibrosis -

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that data from five abstracts on the investigational protein therapeutics, luspatercept and sotatercept, will be presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition being held in San Diego, California on December 3-6, 2016.

The oral and poster presentations will include data from Phase 2 studies with luspatercept, which is being developed under a global partnership with Celgene for the treatment of myelodysplastic syndromes and beta-thalassemia. The clinical presentations at the conference will include updated information beyond that which is contained in the abstracts now available online on the ASH conference website.

Oral presentations

Title: **Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with Beta-Thalassemia** (Abstract #851)

Session: 112. Thalassemia and Globin Gene Regulation: Clinical Advances in Thalassemia

Date: Monday, December 5th

Time: 3:45 p.m. PST (San Diego Convention Center, Room 7AB)

Title: **Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia** (Abstract #478)

Session: 634. Myeloproliferative Syndromes: Clinical: Clinical Trials with Agents Other Than JAK Inhibitors

Date: Sunday, December 4th

Time: 5:15 p.m. PST (Marriott Marquis San Diego Marina, Marriott Grand Ballroom Salons 8-9)

Poster presentations

Title: **Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Anemia Due to Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS): Preliminary Results from Phase 2 Studies** (Abstract #1990)

Session: 637. Myelodysplastic Syndromes - Clinical Studies: Poster I

Date: Saturday, December 3rd

Time: 5:30 - 7:30 p.m. PST (San Diego Convention Center, Hall GH)

Title: **Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study** (Abstract #3168)

Session: 637. Myelodysplastic Syndromes - Clinical Studies: Poster II

Date: Sunday, December 4th

Time: 6:00 - 8:00 p.m. PST (San Diego Convention Center, Hall GH)

Title: **Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Beta-Thalassemia: Preliminary Results from Phase 2 Studies** (Abstract #2463)

Session: 112. Thalassemia and Globin Gene Regulation: Poster II

Date: Sunday, December 4th
Time: 6:00 - 8:00 p.m. PST (San Diego Convention Center, Hall GH)

The luspatercept posters and presentation slides will be available in the "Science" section on Acceleron's website (www.acceleronpharma.com).

About Luspatercept

Luspatercept is a modified activin receptor type IIB fusion protein that acts as a ligand trap for members in the Transforming Growth Factor-Beta (TGF-beta) superfamily involved in the late stages of erythropoiesis (red blood cell production). Luspatercept regulates late-stage erythrocyte (red blood cell) precursor cell differentiation and maturation. This mechanism of action is distinct from that of erythropoietin (EPO), which stimulates the proliferation of early-stage erythrocyte precursor cells. Acceleron and Celgene are jointly developing luspatercept as part of a global collaboration. Phase 3 clinical trials are underway to evaluate the safety and efficacy of luspatercept in patients with myelodysplastic syndromes (the "MEDALIST" study) and in patients with beta-thalassemia (the "BELIEVE" study). For more information, please visit www.clinicaltrials.gov.

About Sotatercept

Sotatercept is an activin receptor type IIA fusion protein that acts as a ligand trap for members in the Transforming Growth Factor-Beta (TGF- β) superfamily involved in fibrosis, vascular calcification, bone mineral density and late stage erythropoiesis (red blood cell production). Acceleron and Celgene are jointly developing sotatercept as part of a global collaboration. Sotatercept is currently in multiple Phase 2 investigator initiated trials. For more information, please visit www.clinicaltrials.gov.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. Its pioneering research platform leverages the powerful biology behind the body's ability to rebuild and repair its own cells and tissues. This approach to drug discovery has generated four therapeutic candidates that are currently in clinical trials. The Company's lead therapeutic candidate, luspatercept, is being evaluated in Phase 3 studies for the treatment of the hematologic diseases, myelodysplastic syndromes (MDS) and beta-thalassemia under a global partnership with Celgene Corp. Acceleron is also advancing clinical programs in the fields of oncology and neuromuscular diseases and has a comprehensive preclinical research effort targeting fibrotic and other serious diseases.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on social media: @AcceleronPharma and LinkedIn.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20161103005459/en/>

Acceleron Pharma Inc.
Todd James, IRC, 617-649-9393
Senior Director, Investor Relations and Corporate Communications
or
Media:
BMC Communications
Brad Miles, 646-513-3125

Source: Acceleron Pharma

News Provided by Acquire Media